Back

Effects of SGLT2 inhibitors on the cardiovascular outcomes in patients with cancer: a systematic review and meta-analysis

1 September 2024 (10:00 - 10:10)
Organised by: Logo
Congress Presentation Part of: Risk prediction and treatment options in cardio-oncology Cardio-Oncology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Assistant Professor Lawrence Yu-Min Liu

Hsinchu MacKay Memorial Hospital, Hsinchu (Taiwan)

4 More presentations in this session

Presentation thumbnail
Adverse cardiovascular events in patients with cancer: a biomarker-enhanced clinical risk score
Doctor S. Kraler (Bern, CH)
Abstract Slides Video
Presentation thumbnail
Sex differences in cancer incidence amongst people with cardiovascular disease: a large British population study.
Miss R. Thuemmler (Aberdeen, GB)
Abstract Slides Video
Presentation thumbnail
An analysis of the virtual cardio-oncology research initiative (VICORI) resource: bleeding risk among cancer patients beyond 1-year post-myocardial infarction
Doctor K. Ow (Leicester, GB)
Abstract Slides Video
Presentation thumbnail
Unveiling the heartbeat of hope: exploring cardiovascular morbidity, mortality, and socioeconomic threads in 65,173 Child, Adolescent, and Young Adult (caya) cancer patients.
Doctor J. Sodling (Norrkoping, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Risk prediction and treatment options in cardio-oncology
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 10:00 CET
You may be interested in
thumbnail
Congress Presentation
The cardioprotective effect of inhibitor sodium glucose transporter in patients undergoing chemotherapy: a systematic review and meta-analysis
thumbnail
Congress Presentation
Indications for SGLT2i to prevent cardiovascular toxicity
thumbnail
Congress Presentation
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in cancer patients with diabetes mellitus

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources